Hephaistos-Pharma
Last verified 2026-05-07. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $2.7Mattributed |
|---|---|
| Latest round | grant, $2.7M, 2023-07-01attributed |
| Founded | unknown |
| Headquarters | Orsay |
| Industry | biotech |
| Stage | unknown |
| Website | hephaistos-pharma.com |
Hephaistos-Pharma develops a third-generation TLR4-agonist small molecule for cancer immunotherapy, with lead candidate HEPHA440 reprogramming suppressive myeloid cells and activating immune responses. It targets oncology patients with myeloid-rich tumors resistant to current immunotherapies. It aims to turn immunologically cold tumors hot via a dual innate-and-adaptive mechanism.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2023-07-01 | grant | $2.7M | undisclosed |
Detected tech stack
PHP 8.2.29, WordPress 6.9.4, Apache HTTP Server, Google Maps, FitVids.JS 4.27.4, jQuery Migrate 3.4.1, CookieYes 3.5.0, Varnish 6.3, Zepto, MySQL, jquery 3., apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Grant, $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Total raised $2.7M | attributed | eu-grant named as publisher. No document URL on file. |
| Company existence | self-reported | hephaistos-pharma.com, read 2026-05-07 |
| Description | self-reported | hephaistos-pharma.com, read 2026-05-07 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.